Stem Cell Clinic

CohBar Announces Proposed Public Offering of Common Stock and Warrants

By Global News Feed

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced a proposed underwritten public offering of shares of the Company’s common stock and accompanying warrants to purchase common stock. Each warrant will be exercisable for 5 years from the closing date of the offering. All of the securities to be sold in the offering are being offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Visit link:
CohBar Announces Proposed Public Offering of Common Stock and Warrants

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

By Global News Feed

CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals

See the original post:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

By Global News Feed

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021. The company’s management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time to discuss its results, business developments, and outlook.

Follow this link:
SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

By Global News Feed

DURHAM, N.C., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tuesday, November 9, 2021.

Read the rest here:
Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

By Global News Feed

JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call on Wednesday, November 10, 2021.

Read more:
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

By Global News Feed

BOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, Brickell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Read more:
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

By Global News Feed

SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended September 30, 2021, at 4:30 p.m. EDT on Tuesday, November 2, 2021. The company’s quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics’ performance for the third quarter of 2021.

Go here to read the rest:
Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

By Global News Feed

TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its business update and financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.

Visit link:
PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

→←